• About Us
  • Contact Us
Wednesday, July 6, 2022
Sada El balad
Supervisor
Elham AbolFateh
Editor in Chief
Mohamed Wadie
  • Home
  • News
  • Business
  • Schools & Universities
  • Arts & Culture
  • Entertainment
  • Hospitality
    • Food & Beverage
    • Travel & Tourism
    • Lodging
    • Recreation
  • Sports
  • MORE
    • Lifestyle
    • Opinion & Analysis
    • Technology
    • In-depth
    • Videos & Features
  • صدي البلد جامعات
  • صدي البلد عقارات
No Result
View All Result
  • Home
  • News
  • Business
  • Schools & Universities
  • Arts & Culture
  • Entertainment
  • Hospitality
    • Food & Beverage
    • Travel & Tourism
    • Lodging
    • Recreation
  • Sports
  • MORE
    • Lifestyle
    • Opinion & Analysis
    • Technology
    • In-depth
    • Videos & Features
  • صدي البلد جامعات
  • صدي البلد عقارات
No Result
View All Result
Sada El balad
Supervisor
Elham AbolFateh
Editor in Chief
Mohamed Wadie

FDA OKs First Systemic Treatment for Alopecia Areata

By Dr. Mohamed L. Elsaie, Professor of Dermatology, Senator at the Egyptian Senate

opinion . by opinion .
11:12 AM June 22, 2022
FDA OKs First Systemic Treatment for Alopecia Areata

By Dr. Mohamed L. Elsaie, Professor of Dermatology, Senator at the Egyptian Senate

Share on FacebookShare on Twitter

The US Food and Drug Administration (FDA) today approved baricitinib oral tablets as the first systemic treatment for adult patients with severe alopecia areata.

The disorder with the hallmark signs of patchy baldness affects millions of people each eyar. In patients with the autoimmune disorder, the body attacks its own hair follicles and hair falls out, often in clumps. In February, the FDA granted priority review for baricitinib in adults with severe AA.

Baricitinib (Olumiant) is a Janus kinase (JAK) inhibitor, which blocks the activity of one or more enzymes, interfering with the pathway that leads to inflammation.

Evidence from Two Trials Led to Announcement
This week’s decision came after review of the results from two randomized, double-blind, placebo-controlled trials (BRAVE AA-1 and BRAVE AA-2) with patients who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT score) for more than 6 months.

Patients in these trials got either a placebo, 2 mg of baricitinib or 4 mg of baricitinib every day. The primary endpoint for both trials was the proportion of patients who achieved at least 80% scalp hair coverage at week 36.

Baricitinib was originally approved in 2018 as a treatment for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF)-blockers. It is also approved for treating COVID-19 in certain hospitalized adults.

Advertisements

Until now, the only treatments for moderate to severe AA approved by the FDA have been intralesional steroid injections, contact sensitization, and systemic immunosuppressants, but they have demonstrated limited efficacy, are inconvenient for patients to take, and have been unsuitable for use long term.

Last month, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of baricitinib for adults with severe AA.

AA received widespread international attention earlier this year at the Academy Awards ceremony, when actor Will Smith walked from the audience up onto the stage and slapped comedian Chris Rock in the face after he directed a joke at Smith’s wife, Jada Pinkett Smith, for her shaved head. Pinkett Smith has AA and has been public about her struggles with the disease.

Related Posts

Air Pollution Disrupts Work in Several Iranian Provinces
LATEST STORIES

Air Pollution Disrupts Work in Several Iranian Provinces

July 6, 2022
NATO's Deputy Secretary General Mircea Geoana
News

NATO: No Plans to Send Troops to Sweden, Finland

July 6, 2022
Kadim Al Sahir
Arts & Culture

Kadim Al Sahir to Perform in North Coast for First Time in 12 Years

July 6, 2022
China Claims to Build More Just World Order
News

China Claims to Build More Just World Order

July 6, 2022
Guardian: Switzerland Opposes  Confiscation of Russia’s Frozen Funds 
Economy

Guardian: Switzerland Opposes  Confiscation of Russia’s Frozen Funds 

July 6, 2022
NASA Loses Radio Connection with CAPSTONE
Technology

NASA Loses Radio Connection with CAPSTONE

July 6, 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Stories

Mostafa Kamel Releases New Song “Wana Batfrag”
Arts & Culture

Mostafa Kamel Releases New Song “Wana Batfrag”

by Ali Abu Dashish
June 29, 2022
0

Prominent Egyptian singer Mostafa Kamel released Tuesday his new song “Wana Batfrag” on YouTube. “Wana Batfrag” is the third track...

George Clooney and Julia Roberts in “Ticket to Paradise”

George Clooney, Julia Roberts Reunite in “Ticket to Paradise” Trailer

June 30, 2022
Amr Diab

Amr Diab Drops Song “El Look El Geded”

June 30, 2022
71% of Americans Do Not Want Biden to Run for 2024  Elections

71% of Americans Do Not Want Biden to Run for 2024  Elections

July 5, 2022
Yemen: 3 Dead, 15 Injured in Explosion at Arms Depot

Yemen: 6 Dead, 23 Injured in Explosion at Arms Depot

July 5, 2022

We Chose for You

Mostafa Kamel Releases New Song “Wana Batfrag”
Arts & Culture

Mostafa Kamel Releases New Song “Wana Batfrag”

by Ali Abu Dashish
June 29, 2022
0

Prominent Egyptian singer Mostafa Kamel released Tuesday his new song “Wana Batfrag” on YouTube. “Wana Batfrag” is the third track...

George Clooney and Julia Roberts in “Ticket to Paradise”

George Clooney, Julia Roberts Reunite in “Ticket to Paradise” Trailer

June 30, 2022
Amr Diab

Amr Diab Drops Song “El Look El Geded”

June 30, 2022
71% of Americans Do Not Want Biden to Run for 2024  Elections

71% of Americans Do Not Want Biden to Run for 2024  Elections

July 5, 2022
Yemen: 3 Dead, 15 Injured in Explosion at Arms Depot

Yemen: 6 Dead, 23 Injured in Explosion at Arms Depot

July 5, 2022
  • News
  • Antiques
  • Travel & Tourism
  • Business
  • Youth & Education
  • Sports
  • Arts & Culture
  • Lifestyle
  • Technology
  • Entertainment
  • Videos & Features
  • Opinion & Analysis

© 2019 see news -powered by 3a digital.

No Result
View All Result
  • Home
  • News
  • Business
  • Schools & Universities
  • Arts & Culture
  • Entertainment
  • Hospitality
    • Food & Beverage
    • Travel & Tourism
    • Lodging
    • Recreation
  • Sports
  • MORE
    • Lifestyle
    • Opinion & Analysis
    • Technology
    • In-depth
    • Videos & Features
  • صدي البلد جامعات
  • صدي البلد عقارات

© 2019 see news -powered by 3a digital.